Abstract
Infections caused by hepatitis C virus (HCV) are a significant worldwide health problem for which novel therapies are urgently needed. One attractive and viable therapeutic target is HCV NS5B RNA dependent RNA polymerase (RdRp) since it is essential for the replication of the viral genome of HCV. The hunt for nonnucleoside inhibitors (NNIs) of HCV NS5B polymerase has led to the identification of several allosteric pockets. However, because the topographical features of these binding sites vary across and even within diverse HCV genotypes, the discovery of new antiviral drugs capable of inhibiting HCV RdRp in the face of variable binding pockets becomes a challenging endeavor. This review focuses on recent accomplishments in the development of new NNIs of HCV NS5B polymerase and on their binding mechanisms to the respective allosteric pockets. Potential difficulties surrounding the discovery of future NNIs targeted to different allosteric pockets of HCV NS5B and to HCV NS5B from different genotypes are also discussed.
Keywords: HCV NS5B polymerase, Allosteric pocket, Nonnucleoside inhibitors, Genotypes, Structure activity relationships
Current Bioactive Compounds
Title: Multiple Allosteric Pockets of HCV NS5B Polymerase and its Inhibitors: A Structure Based Insight
Volume: 4 Issue: 2
Author(s): Tanaji T. Talele
Affiliation:
Keywords: HCV NS5B polymerase, Allosteric pocket, Nonnucleoside inhibitors, Genotypes, Structure activity relationships
Abstract: Infections caused by hepatitis C virus (HCV) are a significant worldwide health problem for which novel therapies are urgently needed. One attractive and viable therapeutic target is HCV NS5B RNA dependent RNA polymerase (RdRp) since it is essential for the replication of the viral genome of HCV. The hunt for nonnucleoside inhibitors (NNIs) of HCV NS5B polymerase has led to the identification of several allosteric pockets. However, because the topographical features of these binding sites vary across and even within diverse HCV genotypes, the discovery of new antiviral drugs capable of inhibiting HCV RdRp in the face of variable binding pockets becomes a challenging endeavor. This review focuses on recent accomplishments in the development of new NNIs of HCV NS5B polymerase and on their binding mechanisms to the respective allosteric pockets. Potential difficulties surrounding the discovery of future NNIs targeted to different allosteric pockets of HCV NS5B and to HCV NS5B from different genotypes are also discussed.
Export Options
About this article
Cite this article as:
Talele T. Tanaji, Multiple Allosteric Pockets of HCV NS5B Polymerase and its Inhibitors: A Structure Based Insight, Current Bioactive Compounds 2008; 4 (2) . https://dx.doi.org/10.2174/157340708785294217
DOI https://dx.doi.org/10.2174/157340708785294217 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Review of the Currently Available Systems to Obtain Platelet Related Products to Treat Equine Musculoskeletal Injuries
Recent Patents on Regenerative Medicine Molecular Response to Hypericin-Induced Photodamage
Current Medicinal Chemistry Computational Evidences of Phytochemical Mediated Disruption of PLpro Driven Replication of SARS-CoV-2: A Therapeutic Approach against COVID-19
Current Pharmaceutical Biotechnology Management of Unusual Not Scar Ectopic Pregnancy: A Multicentre Retrospective Case Series
Current Women`s Health Reviews Immunomics in Skin Cancer - Improvement in Diagnosis, Prognosis and Therapy Monitoring
Current Proteomics Anti-Inflammatory Drugs and Prediction of New Structures by Comparative Analysis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry FANCJ Helicase Operates in the Fanconi Anemia DNA Repair Pathway and the Response to Replicational Stress
Current Molecular Medicine Undermining Tumor Angiogenesis by Gene Therapy: An Emerging Field
Current Gene Therapy Biomarkers of Regenerative Responses to Phenytoin in Periosteal Fibroblasts and Modulation by Histamine; Relevance to Inflammatory Repair
Recent Patents on Biomarkers Current and Emerging Strategies in Bladder Cancer
Anti-Cancer Agents in Medicinal Chemistry A Virtual Screening Approach for the Identification of High Affinity Small Molecules Targeting BCR-ABL1 Inhibitors for the Treatment of Chronic Myeloid Leukemia
Current Topics in Medicinal Chemistry RAGE: A Multi-Ligand Receptor Unveiling Novel Insights in Health and Disease
Current Medicinal Chemistry Editorial [Hot Topic: Influenza Virus Pathogenesis and Drug Targets (Guest Editor: Christopher F. Basler)]
Infectious Disorders - Drug Targets Unusual Food Allergy: AlioideaAllergic Reactions Overview
Recent Patents on Inflammation & Allergy Drug Discovery Solid Lipid Nanoparticles Containing Nimesulide: Preparation, Characterization and Cytotoxicity Studies
Current Nanoscience Sweet on Hedgehogs: Regulatory Roles of Heparan Sulfate Proteoglycans in Hedgehog-Dependent Cell Proliferation and Differentiation
Current Protein & Peptide Science Platelet-derived Growth Factor Receptor-beta is Differentially Regulated in Primary Mouse Pericytes and Brain Slices
Current Neurovascular Research Selective Chemokine Receptor-Targeted Depletion of Pathological Cells as A Therapeutic Strategy for Inflammatory, Allergic and Autoimmune Diseases
Recent Patents on Inflammation & Allergy Drug Discovery Enhanced Free Radical Status of Cancer Cells Success and Failure of Prooxidant/Antioxidant Treatment
Current Signal Transduction Therapy New Developments in Matrices for Ocular Surface Reconstruction
Current Tissue Engineering (Discontinued)